Aerie shares shoot up as investigators take another big step to an NDA with 2nd positive glaucoma PhIII
Aerie Pharmaceuticals is now two for two on its pivotal Phase III studies for Roclatan, a combo drug that combines the generic latanoprost to its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
